(Reuters) - Trimel Pharmaceuticals Corp said its experimental drug to treat hypogonadism, or low testosterone levels, in men met the main goal of a late-stage study. The company said patients who were administered the intranasal drug CompleoTRT for 90 days showed average testosterone levels within the U.S. Food and Drug Administration's efficacy guidance for a testosterone replacement therapy. It added that no drug-related serious adverse events were observed. ... via Health News Headlines - Yahoo! News Read More Here..
No comments:
Post a Comment